Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience-Reference-Cited by-同舟云学术

Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience

Published:2019-06 Issue:6 Volume:19 Page:390-395
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Cooper Jason P.,Khajaviyan Sirin,Smith Stephen D.,Maloney David G.,Shustov Andrei R.,Warren Edus H.,Soma Lorinda A.,Lynch Ryan C.,Ujjani Chaitra,Till Brian,Halpern Anna B.,Gopal Ajay K.,Deeg H. Joachim,Scott Bart L.,Shadman Mazyar

Funder

National Institutes of Health

National Heart, Lung, and Blood Institute

Histogenetics and the Seattle Translational Tumor Research Fund

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference33 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

2. Chronic lymphocytic leukemia: recent progress and current challenges;Woyach;Semin Oncol,2016

3. Chemoimmunotherapy is not dead yet in chronic lymphocytic leukemia;Brown;J Clin Oncol,2017